{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:09:04Z","timestamp":1789470544917,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.jsat.2020.108028","type":"journal-article","created":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T21:40:03Z","timestamp":1589146803000},"page":"108028","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Medication for opioid use disorder treatment and specialty outpatient substance use treatment outcomes: Differences in retention and completion among opioid-related discharges in 2016"],"prefix":"10.1016","volume":"114","author":[{"given":"Melanie S.","family":"Askari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia S.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia M.","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2020.108028_bb0005","doi-asserted-by":"crossref","unstructured":"Bachhuber, M. A., Mehta, P. K., Faherty, L. J., & Saloner, B. (2017). Medicaid coverage of methadone maintenance and the use of opioid agonist therapy among pregnant women in specialty treatment. Medical Care, 55 (12), 985\u2013990. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29135769. doi:https:\/\/doi.org\/10.1097\/MLR.0000000000000803.","DOI":"10.1097\/MLR.0000000000000803"},{"key":"10.1016\/j.jsat.2020.108028_bb0010","author":"Batts"},{"key":"10.1016\/j.jsat.2020.108028_bb0015","doi-asserted-by":"crossref","unstructured":"Blanco, C., Iza, M., Rodriguez-Fernandez, J. M., Baca-Garcia, E., Wang, S., & Olfson, M. (2015). Probability and predictors of treatment-seeking for substance use disorders in the U.S. Drug and Alcohol Dependence, 149, 136\u2013144. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25725934. doi:https:\/\/doi.org\/10.1016\/j.drugalcdep.2015.01.031.","DOI":"10.1016\/j.drugalcdep.2015.01.031"},{"issue":"3","key":"10.1016\/j.jsat.2020.108028_bb0020","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/ADT.0000000000000063","article-title":"Sex differences in substance abuse treatment adherence in the United States","volume":"14","author":"Bornstein","year":"2015","journal-title":"Addictive Disorders & Their Treatment"},{"key":"10.1016\/j.jsat.2020.108028_bb0025","author":"Center for Disease Control (CDC)"},{"key":"10.1016\/j.jsat.2020.108028_bb0035","unstructured":"Chou R., Korthuis P., Weimer M., Bougatsos C., Blazina I., Zakher B., Grusing S., Devine B., & D., M. (2016). Medication-assisted treatment models of care for opioid use disorder in primary care settings. Retrieved from Rockville, MD: www.effectivehealthcare.ahrq.gov\/reports\/final.cfm."},{"key":"10.1016\/j.jsat.2020.108028_bb0040","doi-asserted-by":"crossref","unstructured":"Clark, R. E., Baxter, J. D., Aweh, G., O'Connell, E., Fisher, W. H., & Barton, B. A. (2015). Risk factors for relapse and higher costs among Medicaid members with opioid dependence or abuse: Opioid agonists, comorbidities, and treatment history. Journal of Substance Abuse Treatment, 57, 75\u201380. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25997674. doi:https:\/\/doi.org\/10.1016\/j.jsat.2015.05.001.","DOI":"10.1016\/j.jsat.2015.05.001"},{"key":"10.1016\/j.jsat.2020.108028_bb0045","doi-asserted-by":"crossref","unstructured":"Connery, H. S. (2015). Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions. Harvard Review of Psychiatry, 23(2), 63\u201375. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25747920. doi:https:\/\/doi.org\/10.1097\/HRP.0000000000000075.","DOI":"10.1097\/HRP.0000000000000075"},{"key":"10.1016\/j.jsat.2020.108028_bb0050","doi-asserted-by":"crossref","unstructured":"D'Aunno, T., Park, S. E., & Pollack, H. A. (2019). Evidence-based treatment for opioid use disorders: A national study of methadone dose levels, 2011-2017. Journal of Substance Abuse Treatment, 96, 18\u201322. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30466543. doi:https:\/\/doi.org\/10.1016\/j.jsat.2018.10.006.","DOI":"10.1016\/j.jsat.2018.10.006"},{"key":"10.1016\/j.jsat.2020.108028_bb0030","series-title":"Treatment improvement protocol (TIP) series 44. HHS publication no. (SMA) 13-4056","article-title":"Substance abuse treatment for adults in the criminal justice system - A treatment improvement protocol","volume":"2005","author":"Center for Substance Abuse Treatment (CSAT)","year":"2005"},{"key":"10.1016\/j.jsat.2020.108028_bb0055","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.drugpo.2019.07.006","article-title":"Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States","volume":"73","author":"Davis","year":"2019","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.jsat.2020.108028_bb0060","doi-asserted-by":"crossref","unstructured":"Deck, D., Wiitala, W., McFarland, B., Campbell, K., Mullooly, J., Krupski, A., & McCarty, D. (2009). Medicaid coverage, methadone maintenance, and felony arrests: Outcomes of opiate treatment in two states. Journal of Addictive Diseases, 28(2), 89\u2013102. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19340671. doi:https:\/\/doi.org\/10.1080\/10550880902772373.","DOI":"10.1080\/10550880902772373"},{"key":"10.1016\/j.jsat.2020.108028_bb0065","doi-asserted-by":"crossref","unstructured":"Doyon, S., Aks, S. E., & Schaeffer, S. (2014). Expanding access to naloxone in the United States. Journal of Medical Toxicology, 10(4), 431\u2013434. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25316516. doi:https:\/\/doi.org\/10.1007\/s13181-014-0432-1.","DOI":"10.1007\/s13181-014-0432-1"},{"key":"10.1016\/j.jsat.2020.108028_bb0070","article-title":"Asian American and Pacific Islander substance use treatment completion","author":"Garrison","year":"2018","journal-title":"Psychological Services"},{"key":"10.1016\/j.jsat.2020.108028_bb0075","doi-asserted-by":"crossref","DOI":"10.1111\/1475-6773.13282","article-title":"The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints","author":"Gertner","year":"2020","journal-title":"Health Services Research"},{"issue":"12","key":"10.1016\/j.jsat.2020.108028_bb0080","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1377\/hlthaff.2016.0623","article-title":"Survey highlights differences in Medicaid coverage for substance use treatment and opioid use disorder medications","volume":"35","author":"Grogan","year":"2016","journal-title":"Health Aff (Millwood)"},{"issue":"6 Suppl 3","key":"10.1016\/j.jsat.2020.108028_bb0085","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1016\/j.amepre.2017.12.022","article-title":"Policy pathways to address provider workforce barriers to buprenorphine treatment","volume":"54","author":"Haffajee","year":"2018","journal-title":"American Journal of Preventive Medicine"},{"key":"10.1016\/j.jsat.2020.108028_bb0090","doi-asserted-by":"crossref","unstructured":"Hubbard, R. L., Craddock, S. G., & Anderson, J. (2003). Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS). Journal of Substance Abuse Treatment, 25(3), 125\u2013134. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/14670518.","DOI":"10.1016\/S0740-5472(03)00130-2"},{"issue":"8","key":"10.1016\/j.jsat.2020.108028_bb0095","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","article-title":"National and state treatment need and capacity for opioid agonist medication-assisted treatment","volume":"105","author":"Jones","year":"2015","journal-title":"American Journal of Public Health"},{"issue":"1","key":"10.1016\/j.jsat.2020.108028_bb0100","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jrh.12260","article-title":"Medication-assisted opioid treatment prescribers in federally qualified health centers: Capacity lags in rural areas","volume":"34","author":"Jones","year":"2017","journal-title":"The Journal of Rural Health"},{"key":"10.1016\/j.jsat.2020.108028_bb0105","author":"Kaiser Family Foundation"},{"key":"10.1016\/j.jsat.2020.108028_bb0110","series-title":"States reporting Medicaid coverage of methadone for opioid use disorder treatment","author":"Kaiser Family Foundation","year":"2019"},{"issue":"7","key":"10.1016\/j.jsat.2020.108028_bb0115","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1001\/jamacardio.2019.1651","article-title":"Association of Medicaid expansion with cardiovascular mortality","volume":"4","author":"Khatana","year":"2019","journal-title":"JAMA Cardiology"},{"issue":"12","key":"10.1016\/j.jsat.2020.108028_bb0120","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/MLR.0000000000000821","article-title":"Medicaid coverage expansions and cigarette smoking cessation among low-income adults","volume":"55","author":"Koma","year":"2017","journal-title":"Medical Care"},{"key":"10.1016\/j.jsat.2020.108028_bb0125","doi-asserted-by":"crossref","unstructured":"Kravitz-Wirtz, N., Davis, C. S., Ponicki, W. R., Rivera-Aguirre, A., Marshall, B. D. L., Martins, S. S., & Cerda, M. (2020). Association of Medicaid expansion with opioid overdose mortality in the United States. JAMA Network Open, 3(1), e1919066. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31922561. doi:https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.19066.","DOI":"10.1001\/jamanetworkopen.2019.19066"},{"key":"10.1016\/j.jsat.2020.108028_bb0130","doi-asserted-by":"crossref","unstructured":"Krawczyk, N., Feder, K. A., Fingerhood, M. I., & Saloner, B. (2017). Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. national sample. Drug and Alcohol Dependence, 178, 512\u2013518. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28719885. doi:https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.06.009.","DOI":"10.1016\/j.drugalcdep.2017.06.009"},{"key":"10.1016\/j.jsat.2020.108028_bb0135","doi-asserted-by":"crossref","unstructured":"Krawczyk, N., Feder, K. A., Saloner, B., Crum, R. M., Kealhofer, M., & Mojtabai, R. (2017). The association of psychiatric comorbidity with treatment completion among clients admitted to substance use treatment programs in a U.S. national sample. Drug and Alcohol Dependence, 175, 157\u2013163. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28432939. doi:https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.02.006.","DOI":"10.1016\/j.drugalcdep.2017.02.006"},{"key":"10.1016\/j.jsat.2020.108028_bb0140","doi-asserted-by":"crossref","unstructured":"Krawczyk, N., Mojtabai, R., Stuart, E. A., Fingerhood, M., Agus, D., Lyons, B. C., \u2026 Saloner, B. (2020). Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services. Addiction. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32096302. doi:https:\/\/doi.org\/10.1111\/add.14991.","DOI":"10.1111\/add.14991"},{"key":"10.1016\/j.jsat.2020.108028_bb0145","doi-asserted-by":"crossref","unstructured":"Krawczyk, N., Picher, C. E., Feder, K. A., & Saloner, B. (2017). Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine. Health Aff (Millwood), 36 (12), 2046\u20132053. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29200340. doi:https:\/\/doi.org\/10.1377\/hlthaff.2017.0890.","DOI":"10.1377\/hlthaff.2017.0890"},{"key":"10.1016\/j.jsat.2020.108028_bb0150","doi-asserted-by":"crossref","unstructured":"Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., \u2026 Walley, A. Y. (2018). Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Annals of Internal Medicine, 169(3), 137\u2013145. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29913516. doi:https:\/\/doi.org\/10.7326\/M17-3107.","DOI":"10.7326\/M17-3107"},{"key":"10.1016\/j.jsat.2020.108028_bb0155","doi-asserted-by":"crossref","unstructured":"Mantha, S., Mauro, P. M., Mauro, C. M., & Martins, S. S. (2019). State criminal justice policy context and opioid agonist treatment delivery among opioid treatment admissions, 2015. Drug and Alcohol Dependence, 107654. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31735533. doi:https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.107654.","DOI":"10.1016\/j.drugalcdep.2019.107654"},{"key":"10.1016\/j.jsat.2020.108028_bb0160","doi-asserted-by":"crossref","unstructured":"Marcovitz, D. E., McHugh, R. K., Volpe, J., Votaw, V., & Connery, H. S. (2016). Predictors of early dropout in outpatient buprenorphine\/naloxone treatment. The American Journal on Addictions, 25(6), 472\u2013477. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27442456. doi:https:\/\/doi.org\/10.1111\/ajad.12414.","DOI":"10.1111\/ajad.12414"},{"key":"10.1016\/j.jsat.2020.108028_bb0165","author":"Medicaid and CHIP Payment and Access Commission (MACPAC)"},{"key":"10.1016\/j.jsat.2020.108028_bb0170","doi-asserted-by":"crossref","unstructured":"Mennis, J., & Stahler, G. J. (2016). Racial and ethnic disparities in outpatient substance use disorder treatment episode completion for different substances. Journal of Substance Abuse Treatment, 63, 25\u201333. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26818489. doi:https:\/\/doi.org\/10.1016\/j.jsat.2015.12.007.","DOI":"10.1016\/j.jsat.2015.12.007"},{"key":"10.1016\/j.jsat.2020.108028_bb0175","doi-asserted-by":"crossref","unstructured":"Mennis, J., Stahler, G. J., El Magd, S. A., & Baron, D. A. (2019). How long does it take to complete outpatient substance use disorder treatment? Disparities among Blacks, Hispanics, and Whites in the US. Addictive Behaviors, 93, 158\u2013165. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30711669. doi:https:\/\/doi.org\/10.1016\/j.addbeh.2019.01.041.","DOI":"10.1016\/j.addbeh.2019.01.041"},{"key":"10.1016\/j.jsat.2020.108028_bb0180","author":"Miller"},{"key":"10.1016\/j.jsat.2020.108028_bb0185","doi-asserted-by":"crossref","unstructured":"Mojtabai, R., Mauro, C., Wall, M. M., Barry, C. L., & Olfson, M. (2019). Medication treatment for opioid use disorders in substance use treatment facilities. Health Aff (Millwood), 38(1), 14\u201323. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30615514.","DOI":"10.1377\/hlthaff.2018.05162"},{"key":"10.1016\/j.jsat.2020.108028_bb0190","series-title":"Principles of drug addiction treatment: A research-based guide","article-title":"How long does drug addiction treatment usually last?","author":"National Institute on Drug Abuse","year":"2018"},{"key":"10.1016\/j.jsat.2020.108028_bb0195","doi-asserted-by":"crossref","unstructured":"Nosyk, B., Anglin, M. D., Brissette, S., Kerr, T., Marsh, D. C., Schackman, B. R., \u2026 Montaner, J. S. (2013). A call for evidence-based medical treatment of opioid dependence in the United States and Canada. Health Aff (Millwood), 32(8), 1462\u20131469. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23918492. doi:https:\/\/doi.org\/10.1377\/hlthaff.2012.0846.","DOI":"10.1377\/hlthaff.2012.0846"},{"key":"10.1016\/j.jsat.2020.108028_bb0200","doi-asserted-by":"crossref","unstructured":"Proctor, S. L., Copeland, A. L., Kopak, A. M., Hoffmann, N. G., Herschman, P. L., & Polukhina, N. (2015). Predictors of patient retention in methadone maintenance treatment. Psychology of Addictive Behaviors, 29(4), 906\u2013917. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26098127. doi:https:\/\/doi.org\/10.1037\/adb0000090.","DOI":"10.1037\/adb0000090"},{"key":"10.1016\/j.jsat.2020.108028_bb0205","doi-asserted-by":"crossref","unstructured":"Sahker, E., Toussaint, M. N., Ramirez, M., Ali, S. R., & Arndt, S. (2015). Evaluating racial disparity in referral source and successful completion of substance abuse treatment. Addictive Behaviors, 48, 25\u201329. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25935719. doi:https:\/\/doi.org\/10.1016\/j.addbeh.2015.04.006.","DOI":"10.1016\/j.addbeh.2015.04.006"},{"key":"10.1016\/j.jsat.2020.108028_bb0210","doi-asserted-by":"crossref","unstructured":"Saloner, B., Stoller, K. B., & Barry, C. L. (2016). Medicaid coverage for methadone maintenance and use of opioid agonist therapy in specialty addiction treatment. Psychiatric Services, 67(6), 676\u2013679. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26927578. doi:https:\/\/doi.org\/10.1176\/appi.ps.201500228.","DOI":"10.1176\/appi.ps.201500228"},{"key":"10.1016\/j.jsat.2020.108028_bb0215","doi-asserted-by":"crossref","unstructured":"Sanger, N., Shahid, H., Dennis, B. B., Hudson, J., Marsh, D., Sanger, S., \u2026 Samaan, Z. (2018). Identifying patient-important outcomes in medication-assisted treatment for opioid use disorder patients: A systematic review protocol. BMJ Open, 8(12), e025059. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30518592. doi:https:\/\/doi.org\/10.1136\/bmjopen-2018-025059.","DOI":"10.1136\/bmjopen-2018-025059"},{"key":"10.1016\/j.jsat.2020.108028_bb0220","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3109\/16066351003778726","article-title":"Client factors associated with treatment completion in a substance abuse treatment facility","volume":"18","author":"Scalise","year":"2010","journal-title":"Addiction Research and Theory"},{"key":"10.1016\/j.jsat.2020.108028_bb0225","unstructured":"Simoens, S., Matheson, C., Bond, C., Inkster, K., & Ludbrook, A. (2005). The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence. The British Journal of General Practice, 55 (511), 139\u2013146. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15720937."},{"key":"10.1016\/j.jsat.2020.108028_bb0230","doi-asserted-by":"crossref","unstructured":"Stahler, G. J., Mennis, J., & DuCette, J. P. (2016). Residential and outpatient treatment completion for substance use disorders in the U.S.: Moderation analysis by demographics and drug of choice. Addictive Behaviors, 58, 129\u2013135. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26925821. doi:https:\/\/doi.org\/10.1016\/j.addbeh.2016.02.030.","DOI":"10.1016\/j.addbeh.2016.02.030"},{"key":"10.1016\/j.jsat.2020.108028_bb0235","series-title":"Stata statistical software: Release 15","author":"StataCorp","year":"2017"},{"key":"10.1016\/j.jsat.2020.108028_bb0240","doi-asserted-by":"crossref","unstructured":"Stein, B. D., Dick, A. W., Sorbero, M., Gordon, A. J., Burns, R. M., Leslie, D. L., & Pacula, R. L. (2018). A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees. Substance Abuse, 39(4), 419\u2013425. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29932847. doi:https:\/\/doi.org\/10.1080\/08897077.2018.1449166.","DOI":"10.1080\/08897077.2018.1449166"},{"key":"10.1016\/j.jsat.2020.108028_bb0245","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)"},{"key":"10.1016\/j.jsat.2020.108028_bb0250","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)"},{"key":"10.1016\/j.jsat.2020.108028_bb0255","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)"},{"key":"10.1016\/j.jsat.2020.108028_bb0260","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)"},{"key":"10.1016\/j.jsat.2020.108028_bb0265","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)"},{"key":"10.1016\/j.jsat.2020.108028_bb0270","doi-asserted-by":"crossref","unstructured":"Timko, C., Schultz, N. R., Cucciare, M. A., Vittorio, L., & Garrison-Diehn, C. (2016). Retention in medication-assisted treatment for opiate dependence: A systematic review. Journal of Addictive Diseases, 35(1), 22\u201335. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26467975. doi:https:\/\/doi.org\/10.1080\/10550887.2016.1100960.","DOI":"10.1080\/10550887.2016.1100960"},{"key":"10.1016\/j.jsat.2020.108028_bb0275","author":"US Census Bureau"},{"key":"10.1016\/j.jsat.2020.108028_bb0280","doi-asserted-by":"crossref","unstructured":"Vestal, C. (2016). In fighting an opioid epidemic, medication-assisted treatment is effective but underused. Health Aff (Millwood), 35(6), 1052\u20131057. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27269022. doi:https:\/\/doi.org\/10.1377\/hlthaff.2016.0504.","DOI":"10.1377\/hlthaff.2016.0504"},{"issue":"2","key":"10.1016\/j.jsat.2020.108028_bb0285","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/10826084.2017.1363238","article-title":"Barriers to medications for addiction treatment: How stigma kills","volume":"53","author":"Wakeman","year":"2018","journal-title":"Substance Use & Misuse"},{"key":"10.1016\/j.jsat.2020.108028_bb0290","doi-asserted-by":"crossref","unstructured":"Weiss, R. D., Potter, J. S., Fiellin, D. A., Byrne, M., Connery, H. S., Dickinson, W., \u2026 Ling, W. (2011). Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. Archives of General Psychiatry, 68 (12), 1238\u20131246. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22065255. doi:https:\/\/doi.org\/10.1001\/archgenpsychiatry.2011.121.","DOI":"10.1001\/archgenpsychiatry.2011.121"},{"key":"10.1016\/j.jsat.2020.108028_bb0295","doi-asserted-by":"crossref","unstructured":"Woody, G. E., Poole, S. A., Subramaniam, G., Dugosh, K., Bogenschutz, M., Abbott, P., \u2026 Fudala, P. (2008). Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: A randomized trial. JAMA, 300(17), 2003\u20132011. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18984887. doi:https:\/\/doi.org\/10.1001\/jama.2008.574.","DOI":"10.1001\/jama.2008.574"},{"key":"10.1016\/j.jsat.2020.108028_bb0300","doi-asserted-by":"crossref","unstructured":"Wu, L. T., Zhu, H., & Swartz, M. S. (2016). Treatment utilization among persons with opioid use disorder in the United States. Drug and Alcohol Dependence, 169, 117\u2013127. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27810654. doi:https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.10.015.","DOI":"10.1016\/j.drugalcdep.2016.10.015"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074054721930577X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074054721930577X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:51:56Z","timestamp":1760039516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S074054721930577X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":60,"alternative-id":["S074054721930577X"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2020.108028","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medication for opioid use disorder treatment and specialty outpatient substance use treatment outcomes: Differences in retention and completion among opioid-related discharges in 2016","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2020.108028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108028"}}